Trial
NCT03639987
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Cognitive Dysfunction
Intervention
Aducanumab
Why stopped
Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-16